Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery

PHASE4CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

June 1, 2023

Primary Completion Date

February 5, 2025

Study Completion Date

February 5, 2025

Conditions
Corneal EdemaCorneal DefectAnterior Chamber InflammationOcular PainCorneal StainingVisual OutcomeCME - Cystoid Macular Edema
Interventions
DRUG

Dextenza 0.4Mg Ophthalmic Insert

DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

DRUG

Prednisolone Acetate 1% Oph Susp

Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.

DRUG

Prolensa 0.07% Ophthalmic Solution

Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.

Trial Locations (1)

90067

Advanced Vision Care, Los Angeles

All Listed Sponsors
lead

Nicole Fram M.D.

OTHER

NCT05626478 - Assessing eFficacy and Safety of DEXTENZA 0.4 mg inseRt, Following Cataract Surgery | Biotech Hunter | Biotech Hunter